Beyfortus
(Tislelizumab)Phase 3Monoclonal antibody
BeiGeneTislelizumab is used to treat certain types of lymphoma (blood cancers) by helping the immune system recognize and destroy cancer cells.[1] Beyfortus is currently being investigated across 90 indications[3], with its most advanced program in Phase 3.[1]
Beyfortus is one of 1312 small molecule programs targeting Pancreatic Neoplasm. It is currently in Phase 3.
90
Indications
388
Total Trials
103
Active Trials
1,311
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 90 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Beyfortus
BeiGenePhase 3
Avastin
BBio-Thera Solutions
Preclinical
MS Contin
Merck & Co.Preclinical
Voltaren
NovartisPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Dextromethorphan Hydrobromide
Boehringer IngelheimPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer13 trials
Show 10 more trials
Colorectal Cancer11 trials
Show 8 more trials
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT05841134·25 enrolled
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Recruiting·—·Phase 1·NCT06848465·9 enrolled
Lymphoma10 trials
Show 7 more trials
Esophageal Squamous Cell Carcinoma9 trials
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
Recruiting·—·Phase 1·NCT05984342·50 enrolled
Show 6 more trials
Tislelizumab8 trials
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT07475026·198 enrolled
Show 5 more trials
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07031700·22 enrolled
88 more indications
Hepatocellular Carcinoma8 trials
Show 5 more trials
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05807776·50 enrolled
Advanced Solid Tumors6 trials
Show 3 more trials
Gastric Cancer5 trials
Head and Neck Squamous Cell Carcinoma4 trials
Show 1 more trial
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04814069·38 enrolled
Locally-advanced Rectal Cancer4 trials
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
Recruiting·—·Phase 2/3·NCT06312982·375 enrolled
Lung Cancer4 trials
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
Recruiting·—·Phase 1/2·NCT05886439·60 enrolled
Prostate Cancer3 trials
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05189457·32 enrolled
First-line Treatment3 trials
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Unknown status·—··NCT06034964·60 enrolled
Small Cell Lung Cancer3 trials
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruiting·—·Phase 4·NCT06951841·31 enrolled
Combination Therapy3 trials
Efficacy and Safety3 trials
Adenocarcinoma3 trials
Biliary Tract Cancer3 trials
Chemotherapy3 trials
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
Active, not recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT06124378·60 enrolled
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Unknown status·—·Phase 2·NCT05611879·30 enrolled
Nasopharyngeal Carcinoma3 trials
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Unknown status·—·Phase 2·NCT05448885·50 enrolled
Neoadjuvant Treatment3 trials
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
Not yet recruiting·—·Phase 2·NCT06375109·60 enrolled
Cervical Cancer2 trials
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
Recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT05511623·112 enrolled
Solid Tumors2 trials
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
Not yet recruiting·—·N/A·NCT07396090·13 enrolled
Breast Cancer2 trials
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Unknown status·—·Phase 2·NCT04498793·55 enrolled
Esophageal Cancer2 trials
PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
Completed·—·Phase 2·NCT05880082·118 enrolled
Pancreatic Cancer2 trials
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
Unknown status·—·Phase 2·NCT04902261·140 enrolled
Bladder Cancer2 trials
Metastasis2 trials
Urothelial Carcinoma2 trials
Intrahepatic Cholangiocarcinoma2 trials
Gastroesophageal Junction Adenocarcinoma2 trials
Metastatic Colorectal Cancer2 trials
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT06856837·140 enrolled
Locally Advanced2 trials
Advanced or Metastatic Solid Tumors2 trials
Triple-Negative Breast Cancer2 trials
Maintenance Therapy2 trials
Multiple Cancer1 trial
Unresectable1 trial
Uveal Melanoma1 trial
Prospective1 trial
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04501523·460 enrolled
Other Solid Tumors1 trial
Ovarian Cancer1 trial
Elderly Patients1 trial
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Unknown status·—·Phase 2·NCT04541277·55 enrolled
Patients With Advanced Solid Tumors1 trial
Non-squamous NSCLC1 trial
Esophageal Adenocarcinoma1 trial
Safety and Efficacy1 trial
Monoclonal1 trial
Richter Transformation1 trial
Treatment Failure1 trial
Postoperative Adjuvant Therapy1 trial
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT06238167·40 enrolled
Bladder Carcinoma1 trial
Ascites1 trial
Metastatic Melanoma1 trial
Oropharyngeal Cancer1 trial
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Active, not recruiting·—·Phase 2·NCT06009861·110 enrolled
Neoadjuvant Chemotherapy1 trial
Intestinal Cancer1 trial
Metastatic1 trial
Advanced Malignant Tumors1 trial
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05036798·30 enrolled
Relapsed or Refractory1 trial
Neoadjuvant Chemoimmunotherapy1 trial
Neoadjuvant Immunotherapy1 trial
Liver Transplant1 trial
Oral Squamous Cell Carcinoma1 trial
Neoadjuvant Therapy1 trial
Head Neck Cancer1 trial
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05595590·20 enrolled
Metastatic Nasopharyngeal Cancer1 trial
Liver Metastases1 trial
Treatment1 trial
Conversion Therapy1 trial
Advanced Malignancies1 trial
Advanced or Metastatic NSCLC1 trial
Liver Cancer1 trial
Endometrial Cancer1 trial
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Terminated·—·Phase 1·NCT04906382·2 enrolled
B-cell Malignancies1 trial
Thyroid Cancer1 trial
Esophageal Squamous Carcinoma1 trial
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled
Patients With Locally Advanced Rectal Cancer1 trial
Locally Advanced Colon Cancer1 trial
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT07132008·94 enrolled
Pancreatic Ductal Adenocarcinoma1 trial
Radiotherapy1 trial
Locally Advanced or Metastatic Solid Tumors1 trial
Biliary Tract Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tislelizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]